marneffei (6) infection, administration of antiretroviral agents such as zidovudine (7) , and myelosuppression by infiltrative malignancies (8) or infectious pathogens (6) . Other mechanisms for HIV-related anemia included vitamin B12, folate, and iron deficiencies (9) , and HIVdriven impairment of hematopoietic progenitor cells (10) .
Anemia can cause negative physiological functioning, which results in poor quality of life. Some studies reported that in HIV-infected patients, anemia was associated with disease progression and poor prognosis (11) . Moore et al. (12) demonstrated that treating anemia reduced the risk of death and improved prognosis, indicating the need for periodic screening for and treatment of anemia, especially among patients not yet started on combined antiretroviral therapy (cART). The prevalence of and risk factors for anemia vary remarkably in different regions in China due to different socioeconomic conditions. Shen et al. (13) reported that the overall prevalence of anemia among HIVinfected patients was 51.9% and that anemia was highly prevalent among Chinese adults newly diagnosed with HIV-infection, but that severe anemia was less prevalent in this population. Older age, lower CD4 count, and minority ethnicity are associated with an increased risk of anemia: Mijiti et al. (14) reported that 38.9% of HIV-infected patients in Xinjing Province, China, were anemic at the time of cART initiation, and that Uyghur ethnicity, female sex, lower CD4 count, lower body mass index (BMI), self-reported tuberculosis infection, and oral candidiasis were associated with a higher prevalence of anemia.
Despite the availability of cART in China (15) , confirmatory anti-HIV antibody testing is often performed late, once HIV infection has progressed to AIDS and CD4 counts are low, as many people are unaware of HIV infection (16) . Both clinically advanced disease and low CD4 counts are associated with an increased risk of anemia (17) . In China, the prevalence of anemia varies markedly between different regions (3) , and mild anemia is prone to be neglected in clinical work. The prevalence of and risk factors for anemia, and the association between anemia and prognosis in HIVinfected patients are not well documented in China. Therefore, in this study, we retrospectively studied the baseline, pre-cART prevalence of anemia; the risk factors associated with anemia; and its impact on mortality in HIV-infected patients in Beijing Ditan Hospital, the largest specialized hospital for HIV-infected patients in North China. Further, we analyzed the trends of anemia incidence over the study period, once patients were established on cART.
Materials and Methods

Ethical considerations
This retrospective observational cohort study was approved by the institutional review board of Beijing Ditan Hospital, the Capital Medical University, and complies with principles of the Declaration of Helsinki. Existing routine clinical and therapeutic data were anonymously used and were abstracted from the electronic medical records in Ditan Hospital; hence, the need for informed consent was waived.
Patient selection
We conducted the retrospective study in Beijing Ditan Hospital, the largest designated tertiary care hospital for HIV/AIDS in North China, from June, 2003 to December, 2015. Eligible participants were HIV-infected, confirmed by enzyme-linked immunosorbent assay (ELISA) and Western Blot testing; cART-naïve, ready to initiate treatment; and aged ≥ 18 years. We excluded patients who received interferon or ribavirin, patients with cirrhosis, and pregnant women.
Definitions and outcome
Prior to receiving cART, routine baseline blood tests were performed. Anemia was diagnosed as a hemoglobin level < 110 g/L (women) or < 120 g/L (men). After cART initiation, follow-ups were scheduled at 2nd week, 1 st month, 2 nd month, 3 rd month and every 3 month thereafter. At the time of follow-up, CD4 cell counts were routinely tested every 3 months, and viral load was tested every 6 months. The detail data about enrollment, dead cases and lost to follow-up were shown in Table supplement 1 (Table S1 ).
The primary outcome was death. The date of death was recorded in the electronic medical record system in Ditan Hospital, which helped to provide time from initial diagnosis to death.
The National Free Antiretroviral Treatment Program (NFATP) provides antiretroviral therapy and follow-up for HIV-infected patients in China (18) , and 1-month antiretroviral regimens are provided to HIV-infected patients during first 3 months after initiation of cART, and after that, 3-month regimens are provided to patients, which helps control periodic follow-up rate in HIVinfected patients in China.
Clinical data about baseline evaluation, followup, lost to follow-up and dead cases are recorded in electronic medical records and provided to database in NFATP. Ditan Hospital is an observational sentinel for NFATP, which serves HIV-infected population in Beijing. The patients in our cohort are outpatients, who initiate antiretroviral therapy and receive follow-up in Ditan From June, 2003 to December, 2015, we enrolled 3452 HIV-infected patients into our study. The overall prevalence of anemia prior to initiating cART was 9.76% (n = 337), with mild, moderate, and severe anemia observed in 7.6% (n = 263), 1.9% (n = 66), and 0.2% (n = 8) of patients, respectively ( Table 1) .
Among patients with CD4 cell counts of ≤ 50, 51-199, 200-349, and ≥3 50 × 10 9 /L the prevalence of anemia was 43.0%, 11.0%, 2.7%, and 2.1%, respectively ( Figure 1 and Table 1 ).
Predictors of anemia in HIV-infected patients
As seen in Table 2 
Mortality, stratified by CD4 count category and by anemia
Overall, 1.3% (n = 44) of the cohort died. Among patients with mild, moderate, and severe anemia, mortality was 7.2% (19 of 263), 10.6% (7 of 66), and 12.5% (1 of 8), respectively ( Table 1 ). Figure 2 displays mortality stratified by level of immune suppression (CD4 count category).
Survival analysis
The multivariate Cox regression model indicated that age 40-59 years (adjusted hazard ratio [AHR]: 5.76, Hospital. Mortality was calculated due to unambiguous records in database in NFATP.
We also found some patients were withdrawal during follow-up, and Zhang et al. (19) reported that factors independently associated with a higher likelihood of missed visits included female gender, age > 60 years, HIV transmission via injection drug use or plasma donation, baseline alanine aminotransferase >100 IU/ L, and having more symptoms at antiretroviral therapy initiation.
Data collection
Study participants completed scheduled structured questionnaires, eliciting data on sociodemographic and clinical characteristics including sex, age, height, weight, transmission routes, World Health Organization (WHO) clinical stage, and trimethoprim/sulfamethoxazole (SMX-TMP) co-administration. BMI was calculated as weight (kg) divided by the square of height (m). Baseline laboratory tests were performed to measure CD4 count, HIV viral load, hemoglobin, white cell count, and platelet levels, and to detect hepatitis B (HBV) or C (HCV) virus infection.
Statistical analysis
Descriptive analysis was conducted, using frequency and percentages. Bar charts were used to illustrate the proportion of patients with mild, moderate, and severe anemia, stratified by CD4 count and outcome. Incidence rates were calculated as the number of cases of anemia per 100 person-years, and line charts were used to illustrate the trends in incidence of anemia during the follow-up period.
In this study, univariate logistic regression models were used to determine associations between anemia and the following variables: sex; age; HIV transmission route; WHO clinical stage; BMI; baseline CD4, white cell, and platelet counts; baseline and follow-up HIV viral load; SMZ-TMP co-administration; and baseline HBV/HCV co-infection. Statistically significant variables were fitted into a subsequent multivariate logistic regression models.
Cox proportional hazards models were used to evaluate the impact of anemia on mortality in HIVinfected patients. Kaplan-Meier survival curves were computed to evaluate the survival of HIV-infected patients with and without anemia. Log-rank testing was conducted to evaluate differences in cumulative survival between the two groups. All statistical analyses were performed using SPSS version 19.0 (SPSS Institute, Chicago IL, USA). Alpha was set to 0.05, and 95% confidence intervals (CI) were used. (Table 3) . To clarify the effects of anemia on survival, Kaplan-Meier survival curves were plotted, stratified by presence or absence of anemia ( Figure  3) ; log-rank testing demonstrated that there was a significant difference between the two groups (p < 0.05).
Results
Demographic and clinical characteristics
Incidence of anemia, stratified by sex
In this cohort, 79.8% of study participants were men infected with HIV through homosexual sexual contact. Given that the risk factors for anemia differ by sex, we examined total and sex-specific incidence rates of anemia (Figure 4) . The incidence of anemia in women was significantly higher than that in men (p < 0.05).
Discussion
Hematologic abnormalities are reportedly the most common complications of advanced HIV infection (20) , with anemia being the most common hematologic abnormality. Anemia affects a large proportion of those with advanced-stage HIV-infection. Moreover, anemia is an independent risk factor for morbidity and mortality in HIV-infected patients (11, 15) . The prevalence and incidence of anemia varies in different socioeconomic conditions and clinical settings. In Europe and North America, anemia was found in 35-65% of HIV-infected patients pre-cART (21, 22) . Prevalence rates of 42.9% (3) and 18.9% (1) were reported in Ethiopia and in a rural Ugandan cohort, respectively. In a study conducted in China, Shen at al. (13) reported a prevalence of anemia of 51.9% in patients newly diagnosed with HIV infection. In our study, the prevalence of anemia was 9.76%, lower than observed in previous studies. This low prevalence was remarkable, and may be explained by our study setting: First, patients were managed in a hospital-based setting (23) . This has some advantages over community-based treatment models (24) that are commonly applied in China, including timely diagnosis of HIV infection and early detection of anemia. Healthcare workers in the hospital-based HIV treatment model formed a coordinated team to provide support to individuals with high-risk exposure or to cART-naïve patients (23) , including counseling, earlier HIV testing of individuals at high-risk, periodic CD4 cell count measurement, routine blood tests, and timeous cART initiation. These interventions significantly reduce morbidity and mortality. Second, we included a high proportion of urban residents. Ditan Hospital, an observational sentinel for the National Free Antiretroviral Treatment Program (NFATP) in China (23), serves urban residents in Beijing. Urban study subjects may have received more adequate information about nutrition and routine blood testing than their rural counterparts. Third, cART was initiated at higher CD4 count thresholds than in previous studies. The guidelines for the use of antiretroviral agents in China (25) recommend initiation of cART at a CD4 count < 350 × 10 9 /L, or a CD4 count > 350 × 10 9 /L certain clinical criteria are met. Some studies documented that a CD4 count < 200 × 10 9 /L was associated with myelosuppression and anemia (20) . Thus, initiating cART at a higher CD4 count threshold reduces the risk of anemia.
S e v e r a l m e c h a n i s m s c o n t r i b u t e t o t h e pathophysiology of anemia in HIV-infected patients, including increased destruction and decreased or inadequate production of red blood cells (13, 26) . Alexaki et al. (27) documented that anemia occurred in the absence of opportunistic infections, malignancies, and chemotherapy in HIV-infected patients; hence, HIV itself must be involved in the pathophysiology of hematological abnormalities. Anemia may be associated with three HIV-driven mechanisms (10): i) impaired proliferation of hematopoietic progenitor cells, ii) inhibition of differentiation of hematopoietic progenitor cells into cell lineages, and iii) impairment of stromal cells. Moses et al. (28) demonstrated that stromal cells in the microenvironment of the bone morrow can be infected with HIV, resulting in dysregulation of cytokine expression and decreased red blood cell production. Erythropoietin is a glycoprotein hormone that controls erythropoiesis. Some studies demonstrated erythropoietin resistance as a pathophysiological phenomenon in HIVinfected patients (9) , in which circulating auto-antibodies against endogenous erythropoietin blunted the normal physiological cytokine response to anemia. Vanasse et al. (29) reported that erythropoietin resistance was found in the hematopoietic stem cells of aging individuals, and that senescence was related to enhanced expression of inflammatory cytokines that positively regulated erythropoietin resistance, leading to anemia in older age. Older age was found to be an independent risk factor for anemia in this study.
The most statistically significant risk factors for anemia in HIV-infected patients in this study were age ≥ 40 years, female sex, BMI < 18.5 kg/m 2 , and baseline CD4 count ≤ 199 × 10 9 /L. The higher prevalence of anemia in women might be due to menstrual blood loss that drains iron stores. Lower BMI is related to malnutrition and nutrient deficiencies, including deficiencies of vitamin B12, folate, and iron, which directly result in anemia. Similar to prior findings (3, 20) , our results found a strong independent association between CD4 count ≤ 199 × 10 9 /L and anemia; this association was most pronounced in those with a CD4 count < 50 × 10 9 /L. We also demonstrated that higher baseline HIV viral loads were associated with anemia. Sullivan et al. (30) demonstrated that, as HIV infection progressed and immune status deteriorated, HIV viral loads increased, causing cytokine-mediated myelosuppression and anemia.
Although SMX-TMP administration may cause drug-induced aplastic anemia, several studies (30, 31) failed to find this association. Keisu et al. (31) found that SMX-TMP induced anemia, but that this effect was sporadic. Conversely, Sullivan et al. (30) demonstrated a negative association between SMX-TMP use and anemia, explained by the protective effect of SMX-TMP in preventing infections caused by some opportunistic pathogens (such as Mycobacterium avium complex) that can contribute to the development of anemia. In the present study, we failed to demonstrate an association between SMX-TMP administration and anemia. We also we failed to demonstrate an association between HIV/HCV or HIV/HBV co-infection and anemia. Such co-infections can cause anemia due to interferonassociated antiviral therapy or decompensated cirrhosis. That we did not observe this is most likely explained by our exclusion of those receiving interferon or ribavirin and of those diagnosed with cirrhosis.
In the multivariate Cox regression analysis, we found that anemia was the most statistically significant predictor of mortality in HIV-infected patients. Similarly, Santiago-Rodríguez et al. (17) reported that anemia was the strongest predictor of mortality in a cohort of HIV-infected Hispanics, and that the risk of mortality was proportional to the severity of anemia. In a study involving a large urban HIV clinical practice in the US, Moore et al. (32) indicated that the development of anemia was associated with decreased survival, independent of other prognostic factors. In addition, Mocroft et al. (33) demonstrated that a 10 g/ L decrease in most recent hemoglobin level increased the hazard of death by 57%, implying that prophylactic measures against anemia should be instituted in HIVinfected patients with CD4 counts < 200 × 10 9 /L or in patients with higher HIV viral loads. Such prophylactic measures would include vitamin B12, folate, and iron supplementation, and avoidance of myelosuppressive drugs such as zidovudine. The Chinese national HIV treatment guidelines (25) recommend the use of zidovudine in first-line cART regimens. However, zidovudine should be avoided when initiating cART in patients with the above-mentioned anemia-related risk factors, based on baseline evaluation prior to treatment initiation. Some studies have indicated (3) that use of cART improves anemia, suggesting that cART should be initiated as soon as possible in HIV-infected patients with anemia.
Our study has some limitations. First, this was a retrospective observational study; hence, it was subject to the potential biases inherent in the use of observational data. Second, the study sample selection influenced the findings. The study population comprised urban residents in Beijing, who were treated within a hospital-based HIV treatment model. This limits the generalizability of our findings, as the study sample does not represent the HIV-infected population in China more generally, many of whom are treated within community-based treatment models. Third, data were obtained from baseline evaluation prior to initiating cART. This impeded us from elucidating associations between anemia and variables that change over time.
In summary, the overall prevalence of anemia in cART-naïve patients was 9.76% and mild anemia was most common. Anemia was associated with female sex, older age, lower BMI, lower baseline CD4 count, and baseline higher viral load, but was not associated with route of HIV transmission, WHO clinical stage, baseline HIV viral load, SMZ-TMP coadministration, or baseline HBV/HCV co-infection. Anemia was associated with an increased risk of mortality in cART-naïve patients. These findings should be used to promote awareness among physicians to identify anemia early and to prioritize prevention and intervention strategies for anemia in HIV-infected patients.
